Clinical Utility of Ammonia Concentration as a Diagnostic Test in Monitoring of the Treatment with L-Asparaginase in Children with Acute Lymphoblastic Leukemia

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Protocol I</td><td align="center">5000 IU/m<sup>2</sup>/day—days: 12, 15, 18, 21, 24, 27, 30, and 33 </td></tr><tr><td align="left">Protocol II</td><td align="center">10000 IU/m<sup>2</sup>/day—days: 8, 11, 15, and 18 </td></tr><tr><td align="left">Protocol III</td><td align="center">10000 IU/m<sup>2</sup>/day—days: 1, 4, 8, and 11 </td></tr><tr><td align="left">HR blocks 1–3</td><td align="center">25000 IU/m<sup>2</sup>/day—days: 6 and 11</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

The protocols of the ALL IC 2002 program with L-ASPA administration.

BioMed Research International

tab1

Table 1

Table 1: Clinical Utility of Ammonia Concentration as a Diagnostic Test in Monitoring of the Treatment with L-Asparaginase in Children with Acute Lymphoblastic Leukemia 

Table 1 | Clinical Utility of Ammonia Concentration as a Diagnostic Test in Monitoring of the Treatment with L-Asparaginase in Children with Acute Lymphoblastic Leukemia 